Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

132.68 -1.40 (-1.04%)
Official Closing Price Updated: 7:00 PM EDT, May 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,169,152
Open 132.35
Bid (Size) 132.12 (2)
Ask (Size) 132.95 (2)
Prev. Close 134.08
Today's Range 132.06 - 133.14
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Recommends Buying Apple, Finds This Tech Stock 'Very Interesting'
On CNBC's "Mad Money Lightning Round," Jim Cramer said Apple Inc. is a "buy" after iPhone sales in China saw a 52% year-on-year increase. 
Via Benzinga
Weight-Loss Drug Forecasts Skyrocket To $150B As Novo Nordisk, Eli Lilly Ramp Up Supply
The global market for weight-loss drugs is expected to reach a staggering $150 billion by the early 2030s, a significant increase from the previous forecast of $100 billion. This surge is attributed to... 
Via Benzinga

Performance

YTD
+29.94%
+29.94%
1 Month
+5.17%
+5.17%
3 Month
+7.48%
+7.48%
6 Month
+25.82%
+25.82%
1 Year
+63.36%
+63.36%

More News

Read More
A New Name in Weight Loss Drugs
Via The Motley Fool
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
Via Benzinga
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
Via InvestorPlace
Topics ETFs
Where Will Novo Nordisk Be in 10 Years?
Via The Motley Fool
Ozempic Maker Novo Nordisk's Increasing Influence On Denmark's Employment Raises Economic Concerns
Via Benzinga
Topics Economy
Exposures Economy
LifeMD Can Surge on Its GLP-1 Offerings
Via MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Via The Motley Fool
The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop
Via InvestorPlace
European Equities Close Higher As Traders Bank On Imminent ECB Rate Cut: What's Driving Markets Monday?
Via Benzinga
7 Biotech Stocks to Put on Your Breakthrough Radar
Via InvestorPlace
Chinese Scientists Achieve World's First Diabetes Cure Using Cell Therapy: Report
Via Benzinga
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
Via The Motley Fool
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Elon Musk Says Ozempic 'Will Become Very Cheap' After New Comedy Special Paints It As Weight Loss Drug Only Wealthy People Can Afford
Via Benzinga
Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression
Via Benzinga
Stocks to Buy: 7 Undeniable Dow Darlings to Pile Into Now
Via InvestorPlace
Topics Stocks
Exposures US Equities
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
Via InvestorPlace
Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
Via Benzinga
Exposures Product Safety
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Via Benzinga
NeuroBo Pharmaceuticals Stock Slides Despite Animal Study Showing Wegvoy, Liver Fibrosis Success
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
Via Benzinga
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Via Benzinga
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.